Spots Global Cancer Trial Database for pralatrexate
Every month we try and update this database with for pralatrexate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | NCT00052442 | Lymphoma | pralatrexate | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | NCT01188876 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | carboplatin pralatrexate Folic Acid Vitamin B12 Inj... | 18 Years - | Massachusetts General Hospital | |
| Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | NCT00364923 | Peripheral T-ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma | NCT03356678 | Relapsed or Ref... | Pralatrexate | 18 Years - | Samsung Medical Center | |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | NCT01178944 | Adenocarcinoma ... Esophageal Undi... Gastric Adenoca... Gastric Squamou... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IIIB Esop... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Undifferentiate... | Laboratory Biom... Oxaliplatin Pralatrexate | 18 Years - | Roswell Park Cancer Institute | |
| Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | NCT00364923 | Peripheral T-ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies | NCT01532011 | Advanced Cancer... Solid Tumors | Erlotinib Pralatrexate | 12 Years - | M.D. Anderson Cancer Center | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | NCT02594267 | Peripheral T-Ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors | NCT00024245 | Unspecified Adu... | pralatrexate probenecid | 18 Years - | National Cancer Institute (NCI) | |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | NCT03240211 | PTCL CTCL | Pembrolizumab Pralatrexate Decitabine | 18 Years - 90 Years | University of Virginia | |
| Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors | NCT01206465 | Unspecified Adu... | pralatrexate fluorouracil laboratory biom... DNA analysis high performanc... polymerase chai... nucleic acid se... pharmacological... pharmacogenomic... polymorphism an... | 19 Years - | University of Nebraska | |
| A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy | NCT03150602 | Peripheral T Ce... Progression, Di... | Pralatrexate | 20 Years - | Taiwan Mundipharma Pharmaceuticals Ltd. | |
| Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM | NCT01114282 | Multiple Myelom... | velcade Pralatrexate | 18 Years - | Stanford University | |
| Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) | NCT01183065 | Head and Neck C... | Pralatrexate Wi... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | NCT00004238 | Lung Cancer | pralatrexate | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies | NCT01532011 | Advanced Cancer... Solid Tumors | Erlotinib Pralatrexate | 12 Years - | M.D. Anderson Cancer Center | |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | NCT02594267 | Peripheral T-Ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL | NCT03355768 | Lymphoma, T-Cel... | Romidepsin Pralatrexate | 18 Years - 90 Years | Columbia University | |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | NCT02594267 | Peripheral T-Ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy | NCT01129206 | Adenocarcinoma ... Adenocarcinomas... Recurrent Esoph... Squamous Cell C... Stage IV Esopha... | pralatrexate docetaxel fludeoxyglucose... positron emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | NCT00004238 | Lung Cancer | pralatrexate | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | NCT03598998 | Anaplastic Larg... Nodal Periphera... Recurrent Anapl... Recurrent Angio... Recurrent Enter... Recurrent Folli... Recurrent Hepat... Recurrent Matur... Recurrent Monom... Recurrent Mycos... Recurrent Perip... Refractory Anap... Refractory Angi... Refractory Ente... Refractory Foll... Refractory Hepa... Refractory Matu... Refractory Myco... Refractory Peri... Subcutaneous Pa... | Pembrolizumab Pralatrexate | 18 Years - | City of Hope Medical Center | |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | NCT03161223 | Lymphoma, T-Cel... | Durvalumab Pralatrexate Romidepsin 5-Azacitidine | 18 Years - | University of Virginia | |
| 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | NCT00004238 | Lung Cancer | pralatrexate | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | NCT01482962 | Relapsed Periph... Refractory Peri... | Alisertib Pralatrexate Gemcitabine Romidepsin | 18 Years - | Takeda | |
| Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) | NCT01183065 | Head and Neck C... | Pralatrexate Wi... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | NCT00364923 | Peripheral T-ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | NCT00998946 | Lymphoma, B-Cel... | Pralatrexate Vitamin B12 Folic Acid | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy | NCT01129206 | Adenocarcinoma ... Adenocarcinomas... Recurrent Esoph... Squamous Cell C... Stage IV Esopha... | pralatrexate docetaxel fludeoxyglucose... positron emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | NCT01178944 | Adenocarcinoma ... Esophageal Undi... Gastric Adenoca... Gastric Squamou... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IIIB Esop... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Undifferentiate... | Laboratory Biom... Oxaliplatin Pralatrexate | 18 Years - | Roswell Park Cancer Institute | |
| 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | NCT00052442 | Lymphoma | pralatrexate | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | NCT03161223 | Lymphoma, T-Cel... | Durvalumab Pralatrexate Romidepsin 5-Azacitidine | 18 Years - | University of Virginia | |
| Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT00554827 | Cutaneous T-cel... | Vitamin B12 Folic Acid Pralatrexate | 18 Years - | Acrotech Biopharma Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
